HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

balixafortide

a CXCR4 antagonist

Also Known As:

POL6326

Networked: 7 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - balixafortide: 7
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - balixafortide: 7

Experts

1.	Chevalier, Eric: 2 articles (01/2019 - 01/2017)
2.	Romagnoli, Barbara: 2 articles (01/2018 - 01/2017)
3.	Wach, Achim: 2 articles (01/2018 - 01/2017)
4.	Batur, Gokhan: 1 article (06/2021)
5.	Ermert, Philipp: 1 article (06/2021)
6.	Obrecht, Daniel: 1 article (06/2021)
7.	Zimmermann, Johann: 1 article (06/2021)
8.	Bauersachs, Johann: 1 article (01/2019)
9.	Brinkmann, Eva: 1 article (01/2019)
10.	Dembowsky, Klaus: 1 article (01/2019)

Related Diseases

1.	Infarction (Infarctions) 01/01/2019 - "Intravenous infusion of the clinical-stage POL5551 analogue POL6326 (3 mg/kg at 4, 6, 8, and 10 days) decreased infarct volume and improved left ventricular ejection fraction in pigs. "
2.	Breast Neoplasms (Breast Cancer) 10/13/2023 - "The ErNPs@POL6326 probes readily drained into SLNs when delivered subcutaneously, entering metastatic breast tumor cells specifically via CXCR4-mediated endocytosis. " 01/01/2018 - "The results suggest that balixafortide plus eribulin has potential to provide a new therapeutic option in heavily pretreated patients with metastatic breast cancer and warrants further investigation in randomised trials. " 01/01/2018 - "Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial." 06/30/2021 - "Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer." 01/01/2018 - "The safety and tolerability of balixafortide plus eribulin seems to be similar to that of eribulin or balixafortide monotherapy, and the preliminary activity of the combination seems promising in patients with HER-negative metastatic breast cancer. "
3.	Multiple Myeloma 09/01/2012 - "Among these, AMD3100, also known as Plerixaform (Mozobil by Genzyme), is approved for stem cell mobilisation in patients with leukaemia, while BKT140 (Emory University), POL6326 (Polyphor Ag) and TG-0054 (ChemoCentryx) are currently in clinical trials in combination with chemotherapy for multiple myeloma and leukaemia. "
4.	Neoplasm Metastasis (Metastasis) 10/13/2023 - "These results overall underscore the potential of ErNPs@POL6326 for real-time visualization of SLNs and in vivo screening for SLN metastasis. " 01/01/2023 - "A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis." 10/13/2023 - "To improve detection of SLN metastasis, we developed a second near-infrared (NIR-II) in vivo fluorescence imaging system, pairing erbium-based rare-earth nanoparticles (ErNP) with bright down-conversion fluorescence at 1,556 nm. To visualize SLNs bearing breast cancer, ErNPs were modified by balixafortide (ErNPs@POL6326), a peptide antagonist of the chemokine receptor CXCR4. "
5.	Prostatic Neoplasms (Prostate Cancer) 01/01/2023 - "A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis."

Related Drugs and Biologics

1.	POL5551
2.	eribulin
3.	BKT140
4.	plerixafor
5.	balixafortide
6.	Chemokine Receptors
7.	Granulocyte Colony-Stimulating Factor (G-CSF)
8.	Peptides (Polypeptides)
9.	Erbium
10.	Docetaxel (Taxotere)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Drug Therapy (Chemotherapy)